Molecular modeling and evaluation of binding mode and affinity of artemisinin-quinine hybrid and its congeners with Fe-protoporphyrin-IX as a putative receptor by Mahapatra, Rajani Kanta et al.
open access  www.bioinformation.net Hypothesis
  Volume 8(8)   
 
ISSN 0973-2063 (online) 0973-8894 (print)     
Bioinformation 8(8): 369-380 (2012)  369   © 2012 Biomedical Informatics
 
Molecular modeling and evaluation of binding 
mode and affinity of artemisinin-quinine hybrid 
and its congeners with Fe-protoporphyrin-IX as a 
putative receptor 
 
 
Rajani Kanta Mahapatra1, 2*, Niranjan Behera1 & Pradeep Kumar Naik3 
 
 
1School of Life Sciences, Sambalpur University, Burla, Odisha-768019, India; 2School of Biotechnology, KIIT University, 
Bhubaneswar, Odisha-751024, India; 3 Department of Biotechnology & Bioinformatics, JUIT, Solan, Himachal Pradesh-173 215, 
India; Rajani Kanta Mahapatra – Email: rmohapatra@kiitbiotech.ac.in; *Corresponding author 
 
 
Received April 10, 2012; Accepted April 16, 2012; Published April 30, 2012  
 
 
Abstract: 
A recent rational approach to anti-malarial drug design is characterized as ‛‛covalent biotherapy’’ involves linking of two 
molecules with individual intrinsic activity into a single agent, thus packaging dual activity into a single hybrid molecule. In view 
of this background and reported anti malaria synergism between artemisinin and quinine; we describe the computer-assisted 
docking to predict molecular interaction and binding affinity of Artemisinin-Quinine hybrid and its derivatives with the intra-
parasitic haeme group of human haemoglobin. Starting from a crystallographic structure of Fe-protoporphyrin-IX, binding modes, 
orientation of peroxide bridge (Fe-O distance), docking score and interaction energy are predicted using the docking molecular 
mechanics based on generalized Born/surface area (MM-GBSA) solvation model. Seven new ligands were identified with a 
favourable glide score (XP score) and binding free energy (∆G) with reference to the experimental structure from a data set of thirty 
four hybrid derivatives. The result shows the conformational property of the drug-receptor interaction and may lead to rational 
design and synthesis of improved potent artemisinin based hybrid antimalarial that target haemozoin formation. 
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Background: 
Malaria is a non-contagious disease of chronic evolution that 
manifests in acute episodes [1]. Currently, millions of people in 
the tropical and subtropical zones of the world are affected by 
malaria  [1]. The malaria parasite manifests disease condition 
only during its blood stage in its lifecycle. This part occurs 
largely within the red blood cell of the human host [1], where it 
digests a major proportion of the red cell haemoglobin [2]. It has 
been demonstrated that Plasmodium falciparum, the causative 
agent of almost all fatal cases of malaria, detoxifies host 
haemoglobin-derived ferriprotoporphyrin IX (Fe (III) PPIX) in  
 
 
an acidic digestive vacuole (DV) mainly by converting it to 
haemozoin [2]. Fe (III) PPIX produced by autoxidation of haeme 
(Fe (II) PPIX) released from haemoglobin is known to be 
capable of causing lipid peroxidation [2] and to destabilize 
membranes through a colloid osmotic mechanism [2]. 
Packaging Fe (III) PPIX into compact and highly insoluble 
haemozoin crystals decreases its pro-oxidant capacity [3] and 
likely also avoids colloid osmotic effects. Haemozoin is now 
known to be a crystalline cyclic dimer of Fe(III)PPIX in which 
the propionate group of one porphyrin moiety coordinates to 
the Fe(III) center of its partner and vice versa, while the second BIOINFORMATION  open access 
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propionic acid group of each Fe(III)PPIX hydrogen bonds to a 
neighbouring dimer in the crystal [3]. 
 
The widely used quinoline drugs chloroquine, quinine, and 
mefloquine, as well as amodiaquine and the nonquinoline 
drugs such as halofantrine and lumefantrine are known to act 
against the blood stages of the infection by inhibiting 
detoxification of Fe (III) PPIX into haemozoin, resulting in a 
build-up of toxic Fe (III) PPIX [2, 4] and artemisinin cause a 
similar effect by reacting with haeme (FeII-protoporphyrin IX) 
to give free radicals and adducts [5, 6]. The artemisinins are the 
most effective antimalarial drugs with a remarkable therapeutic 
index  [6]. As a fact World Health Organisation (WHO) has 
advocated the policy of Artemisinin-based combination therapy 
(ACTs) for treating P.falciparum malaria [6]. The rationale for 
this combination is that the artemisinin derivative rapidly clears 
95% of the parasites and the remaining 5% are cleared by the 
longer half-life partner drug and thus the risk of recrudescence 
is minimized. Because of the paucity of promising novel 
antimalarial drugs under development and fear of loss of the 
artemisinin to resistance, in malaria drug combination therapy, 
the current trend is to co-formulate two or more agents into a 
single tablet, as a multicomponent drug [7]. However, based on 
the wide interest in the hybrid molecules as well as numerous 
encouraging efficacy and toxicity reports, the next generation 
antimalarial may well be hybrid drugs as opposed to 
multicomponent ones. There are numerous advantages of 
employing hybrid molecules over multicomponent drugs in 
malaria therapy. Compared to the latter, hybrid drugs may be 
less expensive since, in principle, the risks and costs involved 
may not be different from any other single entity. Another 
advantage is that of the lower risk of drug–drug adverse 
interactions compared to multicomponent drugs [7]. 
 
Figure 1: A) 2D molecular structure of Dihydroartemisinin-
Quinine hybrid; B) 2D structure of Haeme 
 
The mechanism of action of any drug is very important in drug 
development. Generally, the drug compound binds with a 
specific target, a receptor, to mediate its effects. Therefore, 
suitable drug–receptor interactions are required for high 
activity. Understanding the nature of these interactions is very 
significant and theoretical calculations, in particular the 
molecular docking method, seem to be a proper tool for gaining 
such understanding. The docking results obtained will give 
information on how the chemical structure of the drug should 
be modified to achieve of new and more effective drugs. As a 
proof-of-concept and the reported antimalarial synergism 
between artemisinin/other endoperoxides and quinine, we 
conceptualize to evaluate in silico the molecular interaction and 
binding affinity of a covalently linked artemisinin–quinine 
hybrid in which the vinyl functionality of quinine was modified 
to allow for the attachment of dihydroartemisinin (Figure 1A) 
with intra-parasite prosthetic haeme group of human 
haemoglobin [8].The rationale behind the design was to address 
the fact that artemisinin is lipophilic, fast-acting but quickly 
eliminated drugs that is associated with high rates of 
recrudescence when used in monotherapy [9]. It was suggested 
that coupling of the slow-acting, relatively polar quinine 
derivative might increase the half-life of the artemisinin moiety. 
Current research in this field seems to endorse hybrid 
molecules as the next-generation antimalarial drugs [10].  
 
Methodology: 
Preparation of protein 
Studies on the mode of action of artemisinin and its derivatives 
have shown that free haeme could be the molecule targeted by 
artemisinin in biological systems [11-15].Similarity 
spectrophotometric study revealed that quinine and related 
antimalaria drugs interact with Ferriprotoporphyrin-IX [16].   
  
So the X-ray structure of halofantrine-Ferriprotoporphyrin-IX 
(CCDC_659633) from the Cambridge Crystallographic Data 
Centre is used as initial structure in the preparation receptor 
binding site [17]. Ferriprotoporphyrin-IX is a planar molecule 
with a strong positive charge on its central iron atom (Figure 
1B). After removal of halofantrine structure, the charge on the 
iron was assigned as +2 but the structure was kept the same. 
Hydrogen’s were added to the model automatically via the 
Maestro interface [18] leaving no lone pair and using an explicit 
all-atom model. The multi-step Schrödinger’s protein 
preparation tool (PPrep) was used for final preparation of 
receptor model. The complex structure was energy minimised 
using the OPLS-2005 force field and the conjugate gradient 
algorithm, keeping all atoms except hydrogen fixed. The 
minimisation was stopped either after 1000 steps or after the 
energy gradient converged below 0.01 KJ/mol. 
 
Virtual library design 
The virtual library of Artemisinin-Quinine hybrid analogues 
contain 34 compounds divided into nine sub libraries. All these 
compounds are taken from various sources belonging to 
different derivatives of Artemisinin and Quinine [19-26].The 
following physiochemical parameters are considered for design 
of Artemisinin -Quinine hybrid derivatives. (Table 1a-1h, see 
supplementary material). 
 
Log P (partition coefficient) 
The logP value of Artemisinin-Quinine-OH hybrid is estimated 
to be 5.57. In view of background; the logP value is set to be in 
the range of 4.5-6.10 [27]. 
 
Molecular weight 
The molecular weight of the hybrid molecule is estimated to be 
622.74 g/mol. So the molecular weight kept below 650 g/mol to 
enhance the membrane permeability [28]. 
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H-bond donor and acceptor 
In designing inhibitor with reference to hydrogen bond donor 
and acceptor we have refereed to ‘Lipinski rule of 5’ which state 
that hydrogen bond donor and acceptor should not be more 
than 5   and 10 respectively [29, 30]. 
 
Sub lib-I:  
Dihydroartemisinin-Quinine Hybrid-This library consist of only 
of one ligand. The structure is designed experimentally in 
which the vinyl functionality of quinine was modified to allow 
for the attachment of dihydroartemisinin.   
 
Sub lib-II:   
Artemisinin-Quinine Hybrid - This library consists of five 
ligands which are designed by attachment of Quinine moiety to 
the Artemisinin molecule at O-14.  
 
Sub lib-III:  
C9 Artemisinin-Quinine Hybrid- This library consists of two 
ligands in which the C9 substituted Artemisinin entity is 
attached to Quinine at O-14 position. 
 
Sub lib-IV:  
C3 Artemisinin-Quinine Hybrid- C3 substituted Artemisinin 
derivatives are attached to Quinine moiety and two hybrids are 
present in this sub library. 
 
Sub lib-V: 
C10 Artemisinin-Quinine Hybrid- This library consist of five 
ligands in which the C10 carbon atom of Artemisinin is 
modified and Quinine molecule is attached to it at C9 carbon 
atom. 
 
Sub lib-VI:  
Seco Artemisinin-Quinine Hybrid-This library is having three 
ligands (16-18) with logP in the range from 5.22 to 5.79.The 
Quinine molecule is attached to the seco artemisinin entity at C9 
carbon atom. 
 
Sub lib-VII:  
Miscellaneous Artemisinin-Quinine Hybrid- This library 
consists of four ligand in which various substitutions in 
different carbon atom of Artemisinin molecule are attached to 
the Quinine entity. 
 
Sub lib-VIII:  
Quinoline-Artemisinin Hybrid-Quinoline-Artemisinin sub 
library is having twelve ligands in which the various 
substitutions at quinoline ring of the Quinine molecule is 
attached to artemisinin phramacophore. 
 
We used ISIS Draw 2.3 software for sketching structure and 
converting it its 3D representation by using ChemSketch 3D 
viewer of ACDLABS 12.0. LigPrep was used for final 
preparation of ligands from libraries for docking. LigPrep is a 
utility of Schrodinger software suit that combines tools for 
generating 3D structures from 1D (Smiles) and 2D (SDF) 
representation, searching for tatutomers and steric isomers and 
perform a geometry minimization of ligands. The ligands were 
minimized by means of Molecular Mechanics Force Fields 
(OPLS-2005) with default setting. 
 
Docking procedure 
It is quite important to have an accurate model for the haeme-
Art-Qui-OH complex, because this knowledge can be used to 
design better and more potent antimalarial. The Schrodinger 
Glide program version 4.0 has been used for docking. After 
ensuring that receptor and ligand are in the correct form for 
docking, the receptor-grid file was generated using a grid-
receptor generation program. The default size was used for the 
bounding and enclosing boxes. The grid box was generated at 
the centroid of the haeme. The ligands were docked initially 
using the ‘standard precision’ method. The best 10 poses and 
corresponding scores have been evaluated using Glide in single 
precision mode (Glide SP) .The pose with the lowest Glide SP 
score has been taken as the input for the Glide calculation in 
extra precision mode (Glide XP). To soften the potential for non-
polar parts of the receptor, we scaled van der Waals radii of 
receptor atoms by 1.00 with partial atomic charge 0.25. 
 
The docked poses were minimized using the local optimization 
feature in Prime and the energies of complex were calculated 
using the OPLS-AA force field and generalized-Born/surface 
area (GB/SA) continuum solvent model. The binding free 
energy (ΔG bind) is then estimated using equation [31]. 
 
       ΔG bind = E R: L – (ER+EL) +ΔG solv+ ΔGSA              (1) 
 
Where ER:L is energy of the complex, ER  + EL is sum of the 
energies of the ligand and unliganded receptor, using the 
OPLS-AA force field, ΔG  solv (ΔGSA) is the difference between 
GBSA solvation energy (surface area energy) of complex and 
sum of the corresponding energies for the ligand and 
unliganded protein. Corrections for entropic changes were not 
applied in this type of free energy calculation. 
 
Discussion: 
Early reports have revealed that P. falciparum 3D7 strain growth 
was inhibited by much lower concentrations of the hybrid than 
that of quinine or artemisinin alone. This suggested that the 
actions of both quinine and artemisinin moieties were 
preserved. Moreover, when the activity of the hybrid was 
compared with that of a 1:1 mixture of quinine and artemisinin 
(on a mol quinine/mol artemisinin basis), the hybrid was about 
3 fold superior. Similar results were obtained with the 
chloroquine-resistant strain FcB1 Table 2 (see supplementary 
material). 
 
Prompted by the experimental study; a set of Artemisinin-
Quinine hybrid with its 34 analogous structures have been 
computationally analyzed by molecular docking simulation to 
identify new analogues that have a similar mechanism of action 
yet superior activity. Glide 4.0 [32] in XP mode has been used to 
dock the library (I–IX) of Art-Qui-OH with the putative receptor 
Fe-PPIX. Interaction of Art-Qui-OH and its derivatives with Fe 
(II) PPIX (Iron (II)) involves binding between the endoperoxide 
bridges (O1 and O2) bridge of the hybrid to the front of the iron 
bridge of protoporphyrin-IX shown in (Figure 2).   
 
The XP score of the experimental structure; dihydroartemisinin-
quinine compound is computed to -7.485 kcal/mol. Out of 34 
derivatives; seven novel ligands among the library; two from 
C3-Artemisinin-Quinine hybrid, three from C10-Artemisinin-
Quinine hybrid and two from Miscellaneous Artemisinin-BIOINFORMATION  open access 
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Quinine hybrid have better Glide score. Previous studies 
showed that interactions between peroxide linkage in 
artemisinin compounds and haeme iron play major role in the 
binding mode, therefore, distances between haeme iron and 
two peroxide oxygen’s; O1, O2 as well as O11 and O13 and 
∆Gbind of these seven derivatives were monitored.      
 
 
Figure 2: Representative docking Fe-(O1-O2) interaction of 
Dihydroartemisinin-Quinine hyb r i d  w i t h  F e - ( I I )  P P I X  a s  a  
putative receptor 
 
For each of the seven ligands, the pose with the lowest Glide 
score was rescored using Prime/MM-GBSA approach. This 
approach is used to predict the free energy of binding for set of 
ligands to receptor. The ∆Gbind energies among the ligands vary 
in between -49.00 to-32.35 kcal/mol. The calculated relative 
binding energy (ΔΔG  bind-cald) of the ligands was also obtained 
by using Art-Qui-OH as reference. The drop in calculated 
relative binding energy of the ligand provides a favourable 
energetic evaluation of the binding affinity Table 3 (see 
supplementary material). 
 
In any binding energy calculation, the correct binding structure 
of each ligand has to be determined first prior to binding energy 
estimation. Excluding only one structure from C10 Artemisnin-
Quinine hybrid; in other docking configuration it was observed 
that artemisinin moiety of the hybrid prefers to dock at 
endoperoxide oxygen’s (O1 and O2), with O2–Fe as the shortest 
haeme–artemisinin distance and O1–Fe as the second shortest 
distance. Configuration of dihydroartemisinin-quinine hybrid 
had the peroxide oxygen O1 and O2 close to the haeme iron 
(3.273 Å & 2.817 Å) with O11 and O13 atom further removed 
(5.071 Å & 5.149 Å). The ∆Gbind value of the structure is -32.35 
kcal/mol. Configuration of ligand 9 and 10 of C3-Artemisnin-
Quinine hybrid series were almost identical. In both the cases 
O1 (3.281 and 3.282 Å) and O2 (2.817 and 2.825 Å) were closest, 
with other oxygen atom being further away: O11 (4.867 and 
4.951 Å) and O13 (5.125 and 5.172 Å). The docked configuration 
of ligand 11 of C10 Artemisinin-Quinine hybrid the binding 
with the endoperoxide moiety of artemisinin is in a different 
configuration, and a stronger O11–Fe attraction is resulted 
(3.812 Å) than O1, O2 and O13 (6.487 Å, 6.176 Å and 5.325 Å). 
The relative binding energy (ΔΔG  bind-cald) of the ligand is 
calculated to be -10.13 kcal/mol. Such deviation may be 
explained on the basis of stereochemistry of artemisinin 
analogues that is controlled by steric hindrance. The analogues 
which approach the haeme-iron as close as possible will have 
better interaction and thus a good glide score. However, owing 
to the planar structure of the Ferriprotoporphyrin-IX, the 
repulsion between artemisinin and the protoporphyrin ring 
prevents artemisinin from approaching haeme-iron. Ligand 12 
and 14 of this group produce final orientation with a relative 
binding energy ΔΔGbind-cald of -11.76 Kcal/mol and -5.08 
kcal/mol. Both the configuration involved interaction of the 
peroxide-derived oxygen with the Fe atom of protoporphyrin-
IX. In the most favourable configuration between haeme and 
miscellaneous Artemisinin-Quinine hybrid with a Gscore of -
8.913 kcal/mol (the lowest), the iron is between 3.317 and 2.817 
Å from each of the oxygen in the endoperoxide bridge (O1 & 
O2). This structure has the lowest (∆Gbind) score of -49.00 
kcal/mol. From the docking simulation study it revealed that 
the structure as well as orientation of Artemisnin-Quinine 
hybrid with respect to haeme has a significant effect on drug 
action. It could then be concluded that iron in haeme interacts 
with O2 more preferably than O1, a preference which might 
arise from the more negative charge at O2 and the steric 
hindrance at O1. This observation is in agreement with docking 
results reported by Shukla et al. [33].  
 
Artemisinin-Quinine hybrid molecule is novel due to its 
modified structure and has potent anti malaria activities with 
presence of artemisinin consisting of endo-peroxide Bridge. 
Studies suggest that the antimalarial activity of artemisinin is 
due to the interaction of its peroxide group with the prosthetic 
haeme group of human haemoglobin. Reduction of the 
peroxide group may lead to cytotoxic free radicals and 
electrophilic intermediates, which may be able to react which 
may be able to react with specific P.falciparum membrane 
associated proteins, leading to the parasite’s death. As shown 
by Walsh et al., 2007 their hybrid was highly active in vitro 
against the strains of P. falciparum 3D7 (with IC50 value 8.95 nM) 
and Chloroquine resistant strain P.falciparum FcB1 (IC50 value 
9.59 nM).The reported results demonstrate a proof to the 
concept that linkage of artemisinin and quinine is being 
retained in a single molecule and possibly enhances the 
antimalarial activity of the parent compounds. It is likely that 
the hybrid can interact with haeme or its oxidation product 
haematin as a common target since these are both present in the 
eryhrocytic parasite.  
 
There is no doubt that the hybrid molecules show potent and 
novel anti malarial activity. The next major steps, therefore, is to 
experimentally analyze the antimalaria activity by determining 
the IC50 value of Art-Qui-OH and its structural derivatives by 
BHIA (β-haematin inhibitory assay). Though the analogues 
ranged from poor to good binding affinity; the structures are 
yet to be synthesized. The information that we have obtained in 
this study may lead to the design and hopefully (synthesis) of 
more potent hybrid derivatives with receptor as haematin.  
 
Conclusion: 
We propose a model for the binding mode and binding affinity 
of Art-Qui-OH and its derivatives with a putative receptor. This 
model will help the rational design of new artemisinin based 
hybrid anti-malarial that target haemozoin formation. 
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Supplementary material: 
 
Table 1a: Dihydroartemisinin-Quinine hybrid 
Sl. No       Structure    LogP  Molecular   Weight(g/mol)    XP Score (Kcal/mol) 
1. 
O
O
O
O
O
O
N
HO
N
CH3
CH3
O
H3C
H3C
H
H H
 
   5.57        622.68                                    -7.485             
 
Table 1b: Artemisinin-Quinine Analogous 
Sl.No.     Structure  LogP     Molecular   Weight(g/mol)   XP Score (Kcal/mol) 
2.  
O
O
O
O
O
O
N
HO
N
CH 3
CH 3
O
H3C
H3C
H
 
   5.57         622.78               -6.802            
3. 
O
O
O
O
CH3
O
O
N
HO
N
O
H
H
H3C
H3C
 
    5.08         608.72                 -6.914            
4. 
O
O
O
O
O
O
N
HO
N
O
H
C2H5
H3C
CH 3
H3C
 
   6.10             636.77               -6.950    
5. 
O
O
O
O
O
O
N
HO
N
CH 3
O
H3C
H3C
C2H5
 
   6.10             636.77                                -6.932                   BIOINFORMATION  open access 
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6. 
O
O
O
O
O
O
N
HO
N
CH 3
O
H3C
H3C
CH2
 
   5.75           620.73                             -7.241              
 
Table 1c: C9 Artemisinin-Quinine Hybrid 
Sl. No          Structure    LogP    Molecular    Weight(g/mol)            XP Score (Kcal/mol) 
7. 
 
  
O
O
O
O
O
O
N
HO
N
CH3
O
H
H3C
O
H3C
 
 
   5.18             622.70                           
 
           -5.310                           
8. 
O
O
O
O
O
O
N
HO
N
H3C
CH 3
O
H3C
O
H
H
 
   4.92                 636.73                                                     -5.450                            
 
Table 1d: C3 Artemisinin-Quinine Hybrid 
Sl. No.       Structure  LogP  Molecular   Weight(g/mol)       XP Score (Kcal/mol) 
9. 
O
O
H
O
O
O
O
N
HO
N
CH 3
H
H
O
H3C
H3C
 
 5.08               608.72               -7.673                  
10. 
O
O
H
O
O
O
O
N
HO
N
CH3
H
H
O
H3C
C2H5
 
  5.61                622.74                       -7.620                   BIOINFORMATION  open access 
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Table 1e: C10 Artemisinin-Quinine hybrid 
Sl. No.                             Structure  LogP     Molecular   Weight(g/mol)  XP Score(Kcal/mol) 
11. 
N
O
HO
N
H3C
O
O
O
O
CH3
OH
H
H3C
 
5.58         608.76                     -7.722             
12. 
N
O
HO
N
H3C
O
O
O
O
CH3
C3H6OH
H
H3C
 
5.86          650.00                       -7.815         
13. 
N
O
HO
N
H3C
O
O
O
O
CH 3
OH
OH
 
5.36          610.73                     - 6.277         
14. 
N
O
HO
N
H3C
O
O
O
O
CH3
CH 2CHF 2
H
 
5.93          642.77                      -7.622          
15. 
N
O
HO
N
H3C
O
O
O
O
CH3
OEt
OH
 
6.08         638.79                     -6.283         
 
Table 1f: Seco-Artemisinin-Quinine Hybrid 
Sl. No.               Structure  LogP  Molecular   Weight(g/mol)    XP  Score  (Kcal/mol) 
16. 
O
H
O
O
O
O
O
N
N
HO
O
H3C
H
H3C
H3C
 
 5.79                  610.73         -7.070           BIOINFORMATION  open access 
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17. 
O
CH3
O
O
O
H3C
H3C
O
O
N
N
HO
O
H3C
CH 3
 
 5.71              610.73            -5.586       
18. 
O
H
O
O
O
H3C
H3C
O
O
N
N
HO
O
H3C
CH 3
 
5.22                          596.71       -6.914       
 
Table 1g: Miscellaneous Artemisinin-Quinine Hybrid 
Sl. No.                 Structure       LogP    Molecular   Weight(g/mol)    XP Score (Kcal/mol) 
19. 
   
O
O
O
O
O
O
N
HO
N
CH 3
O
H3C
H3C
CH3
 
      5.98          620.73      -7.600              
20. 
O
O
O
O
O
O
N
HO
N
CH3
O
H3C
O
H3C
 
     5.18           622.70     -6.768                  
21. 
O
O
O
O
O
O
N
HO
N
CH3
O
H3C
H3C O
CH3
 
      4.56           636.73      -8.913                            
22. 
O
O
H
CH3
H3C
O H
H
O
N
HO
N
 
    5.02              537.70   -6.671    BIOINFORMATION  open access 
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Table 1h:Artemisinin-Quinoline Derivatives 
Sl.No.               Structure    LogP     Molecular   Weight(g/mol)      XP  Score  (Kcal/mol) 
23. 
O
O
H
O
O
H
O
O
N
HO
N
O
H
CH 3
H3C
CH3
CH3
 
   5.57       622.74                            -5.83           
 24. 
O
O
H
O
O
H
O
O
N
HO
N
H
CH 3
CH 3
H3C
H3C
 
   5.94            606.74                                -7.02        
25. 
O
O
H
O
O
H
O
O
N
HO
N
H
CH 3
H3C
CH3
CH 3
 
      5.94             606.74              -7.30 
26. 
O
O
H
O
O
H
O
O
N
HO
N
H
CH 3
H3C
CH 3
F
F
  
      5.89                       628.70               -5.79    
27. 
O
O
H
O
O
H
O
O
N
HO
N
H
CH 3
H3C
CH 3
CN
 
       5.06                 617.73                              -6.64        BIOINFORMATION  open access 
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28. 
O
O
H
O
O
H
O
O
N
HO
N
H
CH 3
H3C
CH3
S
H3C
  
       5.97                        638.83               -6.77         
29. 
O
O
H
O
O
H
O
O
N
HO
N
H
CH3
H3C
CH3
F
F    
      5.70                  628.70              -6.56      
30. 
O
O
H
O
O
H
O
O
N
HO
N
H
CH 3
H3C
CH 3
H3C
 
     5.94                606.74                -6.69   
31. 
O
O
H
O
O
H
O
O
N
HO
N
H
CH3
H3C
CH 3
CN  
         4.79                       617.73               -6.53 
32. 
O
O
H
O
O
H
O
O
N
HO
N
H
CH 3
H3C
CH 3
S
H3C                      
          5.97                         638.81               -6.58         BIOINFORMATION  open access 
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33. 
O
O
H
O
O
H
O
O
N
HO
N
H
CH 3
H3C
CH 3
Cl  
  5.73         627.16              -6.54    
34. 
O
O
H
O
O
O
O
N
HO
N
CH 3
F
H3C
CH3
H
 
  5.90         610.71            -6.54 
 
Table 2: Fifty percent inhibitory concentration (IC50) of the Artemisinin-Quinine hybrid compared with the individual drugs [8]. 
3D7 (48 hrs)        3D7 (72 hrs)               FcB1 (48 hrs)     FcB2 (72 hrs)   Compound   
IC50/nM/Final/Initial IC50/nM/Final/Initial  IC50/nM/Final/Initial  IC50/nM/Final/Initial 
               Geometric mean IC50/nM (95% confidence limit)   
Quinine    149 (95.1, 232)  73.5 (57.0, 94.6)      96.8 (74.5, 126)  75.3(59.0, 96.1) 
Artemisinin        89.4 (40.7, 60.0)  45.5 (35.3, 58.6)       50.0 (43.7, 57.3)     55.0(39.0, 77.4) 
Art-Qui-OH      8.95 (6.59, 12.2)  10.4 (6.06, 17.9)     9.59 (7.06, 13.0)      10.2(4.73, 21.9) 
Quinine+ Artemisinin a  31.8 (27.4, 37.0)  28.6 (21.5, 38.2)       27.9 (26.5, 29.5)     26.3(24.7, 28.0)   
Activities against cultured, asynchronous, blood-stage P. falciparum strains 3D7 and FcB1 were determined after 48 and 72 h using the parasite 
lactate dehydrogenase assay. Dose–response curves were used to determine the IC50 and the results are expressed as geometric means of IC50 from 
three duplicate determinations. 
 
a  Values represent concentrations of each of quinine and artemisinin in a 1:1 ratio, for example, a combination of 31.8 nM quinine + 31.8 nM 
artemisinin inhibited the growth of 3D7 by 50% after 48 h. 
 
Table 3:  XP Score and Prime-MM-GBSA energy of Art-Qui-OH and its derivatives with Fe (II) PPIX 
Ligand G  Score ∆G bind  ΔΔG bind-cald    Fe-O1 (Å)  Fe-O2 (Å)    Fe-O13 (Å)    Fe-O11 (Å) 
1  -7.485  -32.35   0.00  3.273  2.817   5.149   5.149  
19  -7.600  -34.38  -2.03  3.298  2.853  5.214   4.934  
10   -7.620  -36.57   -4.22   3.282   2.825   5.172   4.951 
14   -7.622  -37.43  -5.08   3.330  2.731   4.998   4.772  
9  -7.673  -41.30   -8.95   3.281   2.817   5.125   4.867  
11  -7.722  -42.48   -10.13   6.487   6.176   5.235   3.812 
12  -7.815  -44.11   -11.76   3.276   2.833   5.083   4.639  
21   - 8.913  -49.00   -16.65   3.317  2.817   5.120   4.786  
All the energy parameters are expressed in kcal/mol 
ΔΔG bind-cald=   ∆G bind-ligand- ∆G Art-Qui-OH             
 